Medical Technologies investigators assess the health of trial subjects throughout the trial by asking subjects about adverse events;
- medical examinations;
- measuring vital signs such as heart rate and blood pressure;
- routine safety tests of blood and urine;
- continuous monitoring of variables such as the ECG and pulse oximetry;
- and trial-specific tests
The investigator follows up:
- all subjects after their last dose of IMP, for period depending on the IMP and the trial;
- subjects with adverse events, including clinically relevant abnormal laboratory results, until they have resolved or it is clear that they are resolving; and
- subjects who withdraw or are withdrawn from a trial, as if they had completed it, providing they agree.